Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Equity Average (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Equity Average for 15 consecutive years, with $523.3 million as the latest value for Q4 2025.

  • Quarterly Equity Average rose 173.28% to $523.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $523.3 million through Dec 2025, up 173.28% year-over-year, with the annual reading at $472.2 million for FY2025, 133.95% up from the prior year.
  • Equity Average hit $523.3 million in Q4 2025 for Ani Pharmaceuticals, up from $252.9 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $523.3 million in Q4 2025 to a low of -$4.6 million in Q2 2023.
  • Historically, Equity Average has averaged $133.9 million across 5 years, with a median of $145.4 million in 2021.
  • Biggest five-year swings in Equity Average: tumbled 269.01% in 2023 and later skyrocketed 9573850.0% in 2024.
  • Year by year, Equity Average stood at $94.1 million in 2021, then surged by 112.14% to $199.7 million in 2022, then plummeted by 100.0% to $2000.0 in 2023, then surged by 9573850.0% to $191.5 million in 2024, then surged by 173.28% to $523.3 million in 2025.
  • Business Quant data shows Equity Average for ANIP at $523.3 million in Q4 2025, $252.9 million in Q3 2025, and $2000.0 in Q2 2025.